CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.96B, above the global median of $1.15B
- FinancialsAltman Z-Score 5.77: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.96BUSDvs all stocks (USD)
Revenue (TTM)
52.04MUSDvs all stocks (USD)
Beta
0.8800xvs all stocks
52-Week Change
-22.10%vs all stocks
Market Capitalization
1.96BUSDvs all stocks (USD)
Enterprise Value
1.38BUSDvs all stocks (USD)
Forward P/E
-5.83xvs Biotechnology peers
Price to Sales (TTM)
37.74xvs Biotechnology peers
Price to Book (MRQ)
3.38xvs Biotechnology peers
Enterprise to Revenue
26.46xvs Biotechnology peers
Enterprise to EBITDA
-4.67xvs Biotechnology peers
Gross Margin
87.68%vs Biotechnology peers
Operating Margin
-865.46%vs Biotechnology peers
Return on Assets (TTM)
-32.88%vs Biotechnology peers
Return on Equity (TTM)
-68.55%vs Biotechnology peers
Revenue (TTM)
52.04MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2590USDUpdated Jul 19, 2026Quarterly Revenue Growth
0.80%vs Biotechnology peers
Gross Profit (TTM)
-175.06MUSDvs all stocks (USD)
EBITDA (TTM)
-294.82MUSDvs all stocks (USD)
Net Income (TTM)
-290.50MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
0.81%vs Biotechnology peers
Operating Cash Flow (TTM)
-226.20MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-148.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
51.95MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
6.57MUSDFY2025 · Dec 31, 2025Gross Profit
45.38MUSDFY2025 · Dec 31, 2025Operating Income
-270.02MUSDvs all stocks (USD)
Pre-tax Income
-265.94MUSDFY2025 · Dec 31, 2025Net Income
-265.94MUSDFY2025 · Dec 31, 2025EBIT
-254.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-247.31MUSDFY2025 · Dec 31, 2025Research & Development
197.10MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
118.30MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
18.36MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
11.84MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.42USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.42USDFY2025 · Dec 31, 2025Basic Shares Outstanding
187.24MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
187.24MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-265.94MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-215.18MUSDFY2025 · Dec 31, 2025Free Cash Flow
-227.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
738.67MUSDFY2025 · Dec 31, 2025Interest Paid
9.03MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-265.94MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
4.32MUSDFY2025 · Dec 31, 2025Stock-based Compensation
43.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.40MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.74MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-887.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-991.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-11.88MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-11.88MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
541.18MUSDFY2025 · Dec 31, 2025Shares Outstanding
218.90MSharesUpdated Jul 19, 2026Float Shares
184.37MSharesUpdated Jul 19, 2026Shares Short
26.70MSharesUpdated Jul 19, 2026Short Ratio
8.46daysvs all stocks
Short % of Shares Outstanding
14.40%vs all stocks
% Held by Insiders
0.94%vs all stocks
% Held by Institutions
95.74%vs all stocks
Total Cash (MRQ)
666.70MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.04USDUpdated Jul 19, 2026Total Debt (MRQ)
79.46MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1366xvs Biotechnology peers
Current Ratio (MRQ)
14.81xvs Biotechnology peers
Book Value per Share (MRQ)
2.66USDUpdated Jul 19, 2026Total Assets
808.06MUSDvs all stocks (USD)
Total Current Assets
782.13MUSDFY2025 · Dec 31, 2025Total Liabilities
153.75MUSDFY2025 · Dec 31, 2025Total Non-current Assets
25.93MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
102.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
50.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
737.06MUSDFY2025 · Dec 31, 2025Accounts Receivable
30.65MUSDFY2025 · Dec 31, 2025Inventory
3.56MUSDFY2025 · Dec 31, 2025Accounts Payable
4.15MUSDFY2025 · Dec 31, 2025Short-term Debt
2.82MUSDFY2025 · Dec 31, 2025Deferred Revenue
0.00USDFY2025 · Dec 31, 2025Long-term Debt
74.15MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
887.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
22.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-1.16BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
654.31MUSDvs all stocks (USD)
52-Week Low
6.23USDUpdated Jul 19, 202652-Week High
16.44USDUpdated Jul 19, 202652-Week Change
-22.10%vs all stocks
Beta
0.8800xvs all stocks
50-Day MA
9.22USDUpdated Jul 19, 2026200-Day MA
10.25USDUpdated Jul 19, 2026Avg 10-Day Volume
2.16MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.82MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.44USDUpdated Jul 19, 2026Other Income / Expense
-2.44MUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 37.74Revenue Growth YoY: 0.01
Financial Health
Altman Z-Score 5.77: safe zoneNotable
Altman Z-Score: 5.77
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.96B, above the global median of $1.15BNotable
Market cap (USD): 1,964,074,411Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Urogen Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GH Research plc
Tier 1ProductionApproval-Gated PipelineRule
Harmony Biosciences Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
Wuhan Healthgen Biotechnology Corp.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Viridian Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Beijing Aosaikang Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Kangtai Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Eos Energy Enterprises Inc.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Vuzix Corporation
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Draganfly Inc.
2 interpretationsCash Elevated Relative to Current Liabilities and Total AssetsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC